BEIJING: China’s Shenzhen Kangtai Biological Products stated on Tuesday (Feb 2) it has accomplished a facility designed to be able to produce 400 million doses of AstraZeneca’s COVID-19 vaccine per year, doubling a capability goal promised in 2020.
“Kangtai is actively pushing forward procedures for the vaccine’s clinical trial and registration in China, and has completed a manufacturing plant and started trial production,” the Shenzhen-based agency stated in a press launch.
The agency obtained rights to provide the AZD1222 vaccine, developed by the Anglo-Swedish drugmaker and Oxford University, in mainland China final year in return for having the capability to produce no less than 200 million doses by the tip of 2021.
The vaccine may be permitted to be used in China by mid-2021 after gathering security knowledge from Phase I and II trials in China and efficacy knowledge from late-stage trials abroad, Leon Wang, head of AstraZeneca’s China operation, stated in November.
SYRINGE MAKERS UNDER PRESSURE
Chinese syringe makers are warning that they might solely be able to fulfil some orders as late as June, as world coronavirus vaccination programmes put unprecedented ranges of strain on their manufacturing facility strains and snarl the nation’s personal vaccine efforts.
Companies informed Reuters that they have been working across the clock, elevating costs and making an attempt to develop manufacturing facility strains. China and India are the world’s greatest producers of syringes, trade executives stated.
Zhejiang KangKang Medical Devices started receiving export contracts for 10 million to 20 million syringes every in December, in contrast with order sizes of about 5 million every earlier than the pandemic, thanks to abroad vaccination programmes, Guo Chun, its normal supervisor, informed Reuters.
The firm, a unit of Wanbangde Pharmaceutical Holding, was including capability to quadruple its manufacturing for sure kinds of syringes by May, however till then can solely partly fulfil massive orders, he stated.